

Victoria N Karetnikova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7086076/publications.pdf>

Version: 2024-02-01

30
papers

166
citations

1162367

8
h-index

1125271

13
g-index

34
all docs

34
docs citations

34
times ranked

320
citing authors

#	ARTICLE	IF	CITATIONS
1	N-terminal propeptide of type III procollagen for predicting diastolic dysfunction in patients with myocardial infarction and preserved ejection fraction. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2494.	0.4	1
2	Participation of the C-terminal propeptide procollagen type I in the formation of cardiofibrosis in patients with myocardial infarction with preserved left ventricular ejection fraction. Russian Journal of Cardiology, 2021, 26, 4137.	0.4	0
3	Fibrosis biomarkers and global myocardial strain in the diagnosis and prediction of diastolic dysfunction in patients with myocardial infarction and preserved ejection fraction. Russian Journal of Cardiology, 2021, 26, 4255.	0.4	2
4	Serum markers of cardiac fibrosis suffering from heart failure with preserved left ventricular ejection fraction upon ST-segment elevation myocardial infarction. Fundamental and Clinical Medicine, 2021, 6, 46-55.	0.1	0
5	Predictors of myocardial fibrosis and loss of epicardial adipose tissue volume in the long-term period after myocardial infarction. Russian Journal of Cardiology, 2020, 25, 31-40.	0.4	4
6	New coronavirus disease (COVID-19) and cardiovascular disease. Complex Issues of Cardiovascular Diseases, 2020, 9, 17-28.	0.3	24
7	The Congress of the American College of Cardiology in review. Complex Issues of Cardiovascular Diseases, 2020, 9, 29-37.	0.3	1
8	Serum procollagens, structural and functional characteristics of the heart in prediction of cardiac fibrosis after myocardial infarction. Siberian Medical Review, 2020, , 75-82.	0.1	0
9	In-hospital changes of echocardiographic parameters and their relationship with the procollagen I C-terminal propeptide in patients with myocardial infarction and preserved left ventricle systolic function. Russian Journal of Cardiology, 2020, 25, 45-51.	0.4	0
10	Visceral adiposity index in patients with coronary artery disease, obesity and type 2 diabetes. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2311.	0.4	2
11	The relationship of the epicardial fat and adipo-fibrokinases in myocardial infarction. Klinicheskaya Laboratornaya Diagnostika, 2020, 65, 533-540.	0.2	1
12	Educational approaches to teaching specialist program "Cardiology and cardiovascular surgery" during lockdown. Complex Issues of Cardiovascular Diseases, 2020, 9, 90-95.	0.3	0
13	Pre-diabetes as an interdisciplinary problem: definition, risks, approaches to the diagnostics and prevention of type 2 diabetes and cardiovascular complications. Russian Journal of Cardiology, 2019, , 83-91.	0.4	12
14	Prevalence of electrocardiographic changes in Kemerovo region according to the data of the ESSE-RF study. Cardiovascular Therapy and Prevention (Russian Federation), 2019, 18, 120-126.	0.4	0
15	Biological markers and cardiac remodelling following the myocardial infarction. Aging, 2019, 11, 3523-3535.	1.4	2
16	CORRELATION OF INFLAMMATION MARKERS AND THE LEVEL OF DIFFUSIONAL CAPACITY OF LUNGS IN PATIENTS WITH MYOCARDIAL INFARCTION. Siberian Medical Review, 2018, , 11-16.	0.1	0
17	POST-INFARCTION REMODELLING AND DIFFUSION CAPACITY OF THE LUNGS: IS THERE ANY CONNECTION?. Siberian Medical Review, 2018, , 66-72.	0.1	0
18	RELATION OF THE MARKERS OF MYOCARDIAL DYSFUNCTION AND SYSTEMIC INFLAMMATION WITH STRUCTURAL AND FUNCTIONAL PARAMETERS OF THE LUNGS IN MYOCARDIAL INFARCTION PATIENTS. Cardiovascular Therapy and Prevention (Russian Federation), 2018, 17, 24-28.	0.4	0

#	ARTICLE	IF	CITATIONS
19	The factors influencing the diffusion capacity of the lung in patients with myocardial infarction.. Klinicheskaia Meditsina, 2018, 96, 328-334.	0.2	0
20	Outcomes of long-term observation period in patients with myocardial infarction undergone radiopaque interventions in the acute period of the disease.. Klinicheskaia Meditsina, 2018, 96, 648-657.	0.2	0
21	Relationship key factor of inflammation and the development of complications in the late period of myocardial infarction in patients with visceral obesity. BMC Cardiovascular Disorders, 2017, 17, 36.	0.7	8
22	The importance of chronic kidney disease for the assessment of risk of adverse outcomes after myocardial infarction. Klinicheskaia Meditsina, 2017, 95, 563-570.	0.2	1
23	Prognostic Value of Soluble ST2 During Hospitalization for ST-Segment Elevation Myocardial Infarction. Annals of Laboratory Medicine, 2016, 36, 313-319.	1.2	17
24	Serum Galectin and Renal Dysfunction in ST-Segment Elevation Myocardial Infarction. Disease Markers, 2016, 2016, 1-6.	0.6	4
25	Early Effects of Treatment Low-Dose Atorvastatin on Markers of Insulin Resistance and Inflammation in Patients with Myocardial Infarction. Frontiers in Pharmacology, 2016, 7, 324.	1.6	16
26	Glucose levels as a prognostic marker in patients with ST-segment elevation myocardial infarction: a case-control study. BMC Endocrine Disorders, 2016, 16, 31.	0.9	17
27	The role of adipose tissue and adipokines in the manifestation of type 2 diabetes in the long-term period following myocardial infarction. Diabetology and Metabolic Syndrome, 2016, 8, 24.	1.2	17
28	Association of inflammatory markers and poor outcome in diabetic patients presenting with ST segment elevation myocardial infarction. Journal of Inflammation Research, 2015, 8, 107.	1.6	3
29	Dose-dependent effects of atorvastatin on myocardial infarction. Drug Design, Development and Therapy, 2015, 9, 3361.	2.0	8
30	Multivessel coronary artery disease, free fatty acids, oxidized LDL and its antibody in myocardial infarction. Lipids in Health and Disease, 2014, 13, 111.	1.2	23